Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy
Koichiro Yamamoto(Kumamoto University), Hisao Ogawa(Kumamoto University Hospital), Kenichi Tsujita(Kumamoto University), Junji Saruwatari(Kumamoto University), Tomohide Abe(Kumamoto University), Tadasuke Chitose(Kumamoto University), Mariko Deguchi(Kumamoto University), Seiji Hokimoto(Kumamoto University), Seigo Sugiyama(Diabetes Care Center), Koichi Kaikita(Kumamoto University), Takamichi Ono(Kumamoto University), H. Miyagawa(Kumamoto University), Kazunori Morita(Kumamoto University), Hitoshi Sumida(Kumamoto Chuo Hospital), Kazuko Nakagawa(Kumamoto University)
Cited by 100
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449